Management of Tryptase Syndrome in Relation to Heart Disease

Diagnostic Criteria and Management

The American Academy of Allergy, Asthma, and Immunology recommends that patients with hereditary α-tryptasemia or mast cell activation syndrome (MCAS) who experience cardiovascular symptoms require aggressive management of mast cell activation episodes with immediate intramuscular epinephrine, combined with prophylactic antihistamine therapy and trigger avoidance to prevent cardiac complications 1, 2
For MCAS diagnosis with cardiac symptoms, the European Academy of Allergy and Clinical Immunology requires documentation of concurrent involvement of at least 2 organ systems (cardiovascular plus one other: dermatologic, respiratory, or gastrointestinal) during acute episodes 1, 2
The American Heart Association suggests that cardiovascular manifestations include hypotension, tachycardia, syncope or near-syncope occurring episodically 1, 2
The American Academy of Allergy, Asthma, and Immunology recommends that acute serum tryptase elevation of >20% + 2 μg/L above the patient's baseline measured during symptomatic episodes on at least 2 separate occasions is diagnostic of MCAS 1, 2

The American Academy of Emergency Medicine recommends administering intramuscular epinephrine 0.01 mg/kg (1:1000 concentration) immediately into the anterolateral thigh (maximum 0.5 mg adults, 0.3 mg children) as first-line treatment with no absolute contraindications 6
The European Resuscitation Council suggests establishing large-bore IV access and administering rapid fluid boluses with normal saline or lactated Ringer's solution at 5-10 mL/kg in first 5 minutes, then 20 mL/kg boluses as needed 7
The American Heart Association recommends positioning the patient in Trendelenburg position for hypotension; sitting up for respiratory distress; recovery position if unconscious 7

The American College of Cardiology suggests that combined H1 and H2 antihistamines are superior to either alone for preventing mast cell activation episodes 7
The European Academy of Allergy and Clinical Immunology recommends identifying and avoiding specific triggers: hot water, alcohol, certain drugs, stress, exercise, hormonal fluctuations, physical stimuli (pressure, friction) 2

The American Society of Anesthesiologists recommends pre-anesthetic treatment with anxiolytics (benzodiazepines), H1 and H2 antihistamines, and possibly corticosteroids to reduce frequency/severity of mast cell activation events 8
The European Society of Anesthesiology suggests avoiding temperature extremes (hypothermia/hyperthermia) and unnecessary trauma that could trigger mast cell activation 8

The American Academy of Emergency Medicine recommends observing patients for at least 4 hours after symptom resolution; extend to 24 hours for severe reactions or those requiring >1 dose of epinephrine 6
The American College of Cardiology suggests obtaining serial tryptase measurements: acute sample during symptoms, second at 1-2 hours, baseline after 24+ hours of symptom resolution 4, 5

The American Academy of Allergy, Asthma, and Immunology notes that hereditary α-tryptasemia increases risk for severe systemic anaphylaxis including spontaneous and insect venom-triggered episodes, making it an inherited risk factor for MCAS 3
The American Heart Association warns that concomitant cardiovascular disease, β-blockers, or ACE inhibitors increase anaphylaxis risk and should be considered when stratifying patient risk 7